| US 7,341,729 B2 | ||
| Recombinant parainfluenza virus expression systems and vaccines | ||
| Aurelia Haller, Boulder, Colo. (US); and Kathleen L. Coelingh, San Francisco, Calif. (US) | ||
| Assigned to MedImmune Vaccines, Inc., Mountain View, Calif. (US) | ||
| Filed on Sep. 03, 2004, as Appl. No. 10/934,864. | ||
| Application 10/934864 is a continuation of application No. 10/252134, filed on Sep. 20, 2002, granted, now 6,811,784, filed on Nov. 02, 2004. | ||
| Application 10/252134 is a continuation of application No. PCT/US01/09091, filed on Mar. 21, 2001. | ||
| Application PCT/US01/09091 is a continuation of application No. 09/531375, filed on Mar. 21, 2000, granted, now 6,764,685. | ||
| Prior Publication US 2005/0147623 A1, Jul. 07, 2005 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 39/00 (2006.01) | ||
| U.S. Cl. 424—192.1 [424/211.1; 435/69.1] | 21 Claims |
| 1. A pharmaceutical composition comprising:
(a) a recombinant parainfluenza virus (PIV) comprising:
(i) nucleotide sequences of a Kansas-strain bovine PIV type 3 genome; and
(ii) one or more heterologous sequence,
wherein said one or more heterologous sequence has been added to said Kansas-strain bovine PIV genome or has been substituted
for nucleotide sequences of said Kansas-strain bovine PIV genome at nucleotide position 5041, nucleotide position 8529, or
the hemagglutinin-neuraminidase glycoprotein gene; and
(b) a pharmaceutically acceptable excipient.
|